These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
651 related articles for article (PubMed ID: 28751463)
1. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression. Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463 [TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709 [TBL] [Abstract][Full Text] [Related]
3. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer. Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526 [TBL] [Abstract][Full Text] [Related]
4. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis. Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538 [TBL] [Abstract][Full Text] [Related]
5. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice]. Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075 [TBL] [Abstract][Full Text] [Related]
6. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. Stark K; Burger A; Wu J; Shelton P; Polin L; Li J PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo. Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957 [TBL] [Abstract][Full Text] [Related]
9. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867 [TBL] [Abstract][Full Text] [Related]
10. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Ford CE; Ekström EJ; Andersson T Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581 [TBL] [Abstract][Full Text] [Related]
11. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. Mishra AK; Abrahamsson A; Dabrosin C Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364 [TBL] [Abstract][Full Text] [Related]
13. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. Wang J; Xu Y; Li L; Wang L; Yao R; Sun Q; Du G Cancer Med; 2017 Jan; 6(1):275-287. PubMed ID: 28028927 [TBL] [Abstract][Full Text] [Related]
14. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer. Salahuddin A; Ghanem H; Omran GA; Helmy MW Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988 [TBL] [Abstract][Full Text] [Related]
16. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813 [TBL] [Abstract][Full Text] [Related]
17. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells. Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411 [TBL] [Abstract][Full Text] [Related]
18. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095 [TBL] [Abstract][Full Text] [Related]
19. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers. Shome R; Ghosh SS ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052 [TBL] [Abstract][Full Text] [Related]
20. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]